Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Glaukos ( (GKOS) ) just unveiled an announcement.
On July 30, 2025, Glaukos Corporation announced its financial results for the second quarter ended June 30, 2025, reporting record net sales of $124.1 million, a 30% increase year-over-year. The company also raised its 2025 net sales guidance, reflecting strong growth driven by strategic execution and advancements in its pipeline of novel, dropless platform technologies aimed at improving patient outcomes in chronic eye diseases.
The most recent analyst rating on (GKOS) stock is a Buy with a $131.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.
Spark’s Take on GKOS Stock
According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.
Glaukos’ overall score reflects its strong revenue growth and a solid financial position as key strengths, while ongoing profitability and cash flow challenges weigh heavily. Technical indicators suggest a neutral trend, and valuation remains unattractive due to negative earnings. Recent corporate events and pipeline advancements provide some positive outlook.
To see Spark’s full report on GKOS stock, click here.
More about Glaukos
Glaukos is an ophthalmic pharmaceutical and medical technology company that specializes in developing and commercializing innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) and markets the only FDA-approved corneal cross-linking therapy for keratoconus.
Average Trading Volume: 950,255
Technical Sentiment Signal: Hold
Current Market Cap: $5.42B
Find detailed analytics on GKOS stock on TipRanks’ Stock Analysis page.